 SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 GLOBE NEWSWIRE -- Day One Biopharmaceuticals Nasdaq: DAWN, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced the appointment of Scott Garland to the Companys board of directors. Mr. Garland is a 30-year veteran of the biopharmaceutical industry with deep commercial and executive leadership experience. 